A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Condition:   Autosomal Recessive Polycystic Kidney Disease (ARPKD) Intervention:   Drug: Tolvaptan (OPC-41061) Sponsor:   Otsuka Pharmaceutical Development& Commercialization, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials